Elevance Health Inc.
NYSE:ELVMedical - Healthcare Plans
-$3.45 today
- Market cap
- $86.60B
- Beta
- 0.68
- P/E (TTM)
- 16.3
- EPS (TTM)
- $23.78
- Dividend yield
- 1.77%
Volume 1.91M
Average 1.68M
ELV Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Elevance Health Inc.NYSE: ELV
Other Income / Expenses · Q3 FY2026 · quarter ended Sep 2026
Other income / expenses remains negative
Q3 FY2026 other income / expenses was -$358M, compared with -$351M a year earlier. Trailing-twelve-month other income / expenses was -$1.21B.
Context
- Other income / expenses amounted to 0.7% of revenue in FY2025, up 0.1 pp from a year earlier.
- Other income / expenses grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other income / expenses holds near -$358M or moves back toward the trailing-twelve-month quarterly average of -$301.75M.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- (1.4B) USD
- Year-over-year change
- -42.5%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.4B) | -42.5% |
| FY2024 | 2024-12-31 | (984M) | +4.5% |
| FY2023 | 2023-12-31 | (1.03B) | -21.0% |
| FY2022 | 2022-12-31 | (851M) | +16.7% |
| FY2021 | 2021-12-31 | (1.02B) | — |
Other Income / Expenses vs competitors
How ELV compares with its peers on the latest reported figures
- ELV's LTM Sep 2026 other income / expenses of -$1.21B is the 6th highest of the 9 companies compared; the peer median is -$240M.
- Its year-over-year change of +12.3% is the 2nd highest of 8, against a peer median of -1.7%.
- Other income / expenses amounts to 0.6% of revenue for ELV, versus a peer median of 0.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $826.41M | -1.7% | +11.4% | 0.4% | |
| LTM Mar 2026 | -$15.83M | +36.6% | — | 0.4% | |
| LTM Jun 2026 | -$34.29M | -91.3% | — | 0.2% | |
| LTM Sep 2026 | -$213M | -22.4% | — | 0.5% | |
| LTM Sep 2026 | -$267M | — | — | 0.2% | |
| LTM Sep 2026 | -$1.21B | +12.3% | — | 0.6% | |
| LTM Sep 2026 | -$1.32B | -12.0% | — | 0.5% | |
| LTM Jun 2026 | -$2.5B | -1.7% | — | 0.6% | |
| LTM Sep 2026 | -$4.19B | -1.0% | — | 0.9% | |
| Peer median (excluding ELV) | -$240M | -1.7% | +11.4% | 0.4% | |
Competitors are the stored peer set for ELV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 138.64B | 156.6B | 171.34B | 176.81B | 199.13B |
| Cost of Revenue | 102.65B | 116.64B | 124.33B | 127.57B | 148.22B |
| Gross Profit | 35.99B | 39.95B | 47.01B | 49.24B | 50.9B |
| Gross Margin | 26.0% | 25.5% | 27.4% | 27.9% | 25.6% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses | 27.05B | 31.5B | 38.27B | 40.36B | 42.79B |
| Depreciation & Amortization | 1.3B | 1.68B | 1.75B | 1.39B | 1.55B |
| EBITDA | 10.03B | 10.13B | 10.49B | 10.48B | 9.66B |
| EBITDA Margin | 7.2% | 6.5% | 6.1% | 5.9% | 4.9% |
| Operating Income | 8.95B | 8.45B | 8.75B | 8.89B | 8.11B |
| Operating Margin | 6.5% | 5.4% | 5.1% | 5.0% | 4.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 798M | 851M | 1.03B | 1.19B | 1.4B |
| Other Income / Expenses | (1.02B) | (851M) | (1.03B) | (984M) | (1.4B) |
| Income Before Tax | 7.93B | 7.6B | 7.72B | 7.9B | 6.71B |
| Pre-Tax Margin | 5.7% | 4.9% | 4.5% | 4.5% | 3.4% |
| Income Tax Expense | 1.83B | 1.71B | 1.72B | 1.93B | 1.05B |
| Net Income | 6.1B | 5.89B | 5.99B | 5.98B | 5.66B |
| Net Margin | 4.4% | 3.8% | 3.5% | 3.4% | 2.8% |
| EPS (Basic) | 25.25 | 24.56 | 25.38 | 25.81 | 25.18 |
| EPS (Diluted) | 24.73 | 24.28 | 25.22 | 25.68 | 25.12 |
| Weighted Avg Shares | 243.8M | 240M | 233.07M | 232.87M | 221.8M |
| Weighted Avg Shares (Diluted) | 246.8M | 242.8M | 237.4M | 232.9M | 221.8M |
Elevance Health Inc.
NYSE:ELV
Intrinsic Alpha fair value
Locked
Current Price
$400.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.